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Progressive disease (PD) remains the main cause of treat-
ment failure following reduced-intensity conditioning (RIC)
allogeneic stem cell transplantation (allo-SCT) in Hodgkin
lymphoma (HL). In 08/2007 we elected to add gemcitabine
(G) to our standard ﬂudarabine (F) - melphalan (M) RIC
(Anderlini et al, Haematol 93:257, 2008) in patients with
relapsed/refractory HL undergoing allo-SCT. Subsequently,
brentuximab vedotin (BV) was introduced as salvage therapy
prior to allo-SCT. Main G-associated non-hematologic toxic-
ities are pulmonary, skin toxicity and mucositis. Between 8/
07 and 04/13, twenty-seven HL patients underwent an allo-
SCT with the G-FM regimen. The median age was 31 years
(20-46). Disease status at SCT was complete remission (CR)
or undetermined (CRu) (n¼17; 63%), partial remission (n¼9;
33%), and other (n¼1; 4%). The median time to PD after auto-
SCT was 5 months (range 1-68). Fourteen patients (52%)
received BV prior to allo-SCT, and in seven (50%) it was the
last therapy prior to allo-SCT. In these seven patients the CR
rate after BV was 100%. The donor was an HLA-identical
sibling (n¼16) or matched unrelated donor (n¼11). The
conditioning regimenwas G 800 mg/m sq IV x1; F (33 mg/m
sq IV x4), M (70 mg/m sq x2). There were three early (ie
before day 30) deaths and one case of graft failure. Cumu-
lative incidence of day 100 and overall transplant-related
mortality (TRM) was 15% (both). Pulmonary toxicity (NCI CTC
v3) was seen in 9 patients (33%). Grade 4-5 pulmonary
toxicity was seen in 3 patients (13%). Otherwise it was grade
1-3 (n¼6). Cutaneous toxicity (skin rash) was seen in 5 pa-
tients (19%: grade 3 n¼1; grade 1-2 n¼4). Mucositis was seen
in 13 patients (48%). It was grade 3 (n¼1) and grade 1-2
(n¼12). The overall response rate (CR/CRu) prior to allo-SCT
was 79% (11/14) in BV-treated patients vs. 46% (6/13) in BV-
naïve patients (p¼0.12; Fisher’s exact). The overall response
rate (CR/CRu) after allo-SCT was 85%, both in BV+ and in BV-
patients. Six patients expired (TRM n¼4; PD n¼2). Twenty-
one patients are alive with a median follow-up of 18 months
(range 4-55). At the last f/up, actuarial estimates of overall
survival (OS) and progression-free survival (PFS) are 69% and
55%, respectively. Cumulative overall PD incidence is 30%.The median time to PD after allo-SCT is 13 mo (2-22). The
seven patients who received BV as last line of therapy prior to
allo-SCT are all alive and in CR/CRu. The G-FM140 regimen
continues to show promise in this high-risk patient group.
The inclusion of G may affect pulmonary toxicity, but TRM
remained low. With the current BV-supported approach, the
CR rate pretransplant may be improved. PFS (18-mo) in CR/
CRu patients seems to compare favorably to our FM140
experience in complete responders (80% vs 57%, p¼0.2).
While this BV-based transplant strategy needs further eval-
uation, the role of RIC allo-SCT in HL may need reassessment
in the BV era.75
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Background: Nonmyeloablative allogeneic hematopoietic
cell transplantation (NMAT) can produce long-term re-
missions in patients (pts) with relapsed/refractory B-cell
non-Hodgkin lymphoma (B-NHL), yet relapse after NMAT is
the major cause of failure. Radioimmunotherapy (RIT) is
highly effective in relapsed B-NHL with rare non-hemato-
logic toxicity, making it potentially useful in providing early
post-NMAT disease control. We thus performed a phase II
study of 90Y-ibritumomab tiuxetan prior to ﬂudarabine/2 Gy
total body irradiation (TBI)-based NMAT in pts with re-
fractory B-NHL, which yielded the best outcomes in indolent
B-NHL (iB-NHL) (Gopal, Blood, 2011). In order to estimate the
potential beneﬁt of RIT + NMAT in iB-NHL we compared
outcomes of these patients with those treated without RIT
prior to NMAT.
Methods: Comparison patients included consecutive in-
dividuals with iB-NHL who received NMAT from matched
related or unrelated donors following ﬂudarabine/2 Gy TBI
and who met eligibility criteria for the phase II trial of RIT +
NMAT but did not enroll. Frequencies of characteristics be-
tween groups were compared using a Fisher’s exact test.
Kaplan-Meier (K-M) curves were used to estimate the
probabilities of overall survival (OS) and progression-free
survival (PFS). To account for imbalanced covariates,
adjusted estimates of survival were also generated (Storer,
Lifetime Data Anal, 2008).
Results: The RIT + NMAT group included 18 pts with iB-NHL:
chronic lymphocytic leukemia/small lymphocytic lymphoma
(CLL/SLL; n ¼ 10), follicular lymphoma (FL; 6), marginal zone
lymphoma (MZL; 1), and hairy cell leukemia (HCL; 1). Controls
included 73 pts: CLL/SLL (53), FL (19), and MZL (1). The RIT-
treated pts had more bulky disease > 5 cm (61% vs 17%, p <
0.001), chemoresistant disease (72% vs 32%, p ¼ 0.003),
Figure 1.
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and pre-NMAT platelets < 25k/uL (33% vs 8%, p ¼ 0.01). In an
unadjusted comparison, OS and PFS favored the RIT pts, but
the differences were not statistically signiﬁcant (hazard ratio
[HR] for OS ¼ 0.60, 95% conﬁdence interval [CI]: 0.3-1.4, p ¼
0.24; HR for PFS ¼ 0.75, 95% CI: 0.4-1.5, p ¼ 0.41). However,
after adjusting for signiﬁcant differences between these
groups, outcomes for the RIT-treated group were signiﬁcantly
better (HR for OS¼ 0.30; 95% CI: 0.1-0.8, p¼ 0.007; HR for PFS
¼ 0.42, 95% CI: 0.2-0.9, p ¼ 0.02). With a median follow-up of
81months in surviving patients, the 3-year adjusted estimates
for the RIT and control groups were: OS 87% and 59%, PFS 71%
and 44%, respectively (Figures 1 and 2).
Conclusions: These data suggest that the addition of 90Y-
ibritumomab tiuxetan prior to NMATmay result in improved
OS and PFS for patients with persistent iB-NHL. These results
set the stage for a prospective randomized comparison of
these strategies in this setting.
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Introduction: Many patients with high-risk lymphoma
will experience relapse after autologous stem cell trans-
plantation (AutoSCT). There are no therapies given to pa-
tients in remission after AutoSCT which are of proven
beneﬁt. At time of disease relapse after AutoSCT, patients
are often considered for allogeneic stem cell trans-
plantation (AlloSCT) if remission can be achieved by salvage
strategies.
Methods: We conducted a phase II clinical trial of tandem
AutoSCT followed by reduced intensity conditioning (RIC)
AlloSCT for patients with high-risk lymphoma. High-dose
chemotherapy was BuCyE: busulfan (11.2 mg/kg IV total),
cyclophosphamide (120 mg/kg IV total), and etoposide (30
mg/kg IV total). RIC AlloSCT was performed any time be-
tween 40 days and 6 months after AutoSCT if disease had not
progressed. RIC was busulfan (3.2 mg/kg IV total) with ﬂu-
darabine (120 mg/kg IV total) with GVHD prophylaxis
comprised of tacrolimus, sirolimus, and methotrexate.
Results: A total of 42 patients were enrolled. All patients
had at least a partial remission to their last therapy. Eligible
patients in the up-front setting included T-cell lymphoma,
mantle cell lymphoma, and B-cell lymphoma with concur-
rent c-MYC and BCL-2 overexpression or translocations.
Other histologies were required to be relapsed / refractory
as deﬁned by number of lines of therapy or remission
duration < 12 months. All patients underwent BuCyE
AutoSCT. RIC AlloSCT was performed in 29 patients, 16 from
a matched related donor and 13 from a matched unrelated
donor. RIC AlloSCT was not performed in 13 patients
because of patient choice (n¼4), lack of a suitably matched
donor (n¼2), disease progression (n¼6), and therapy-
related AML (n¼1). There has been no transplant-related
mortality from AutoSCT. Of the 29 patients who underwent
both HSCT procedures, median time from AutoSCT to
AlloSCT was 96 days (range 48-169). All patients engrafted
successfully with day 100 median donor chimerism being
95% (range 85-99). The 6-month cumulative incidence of
grades II-IV acute GVHD was 7% (95% CI, 0.3%, 20%). Cu-
mulative incidence of chronic GVHD at one year was 36%
(17%, 56%). Non-relapse mortality at one year was 4.6%
(0.3%, 20%) with one death from sepsis. Cumulative inci-
dence of disease relapse was 20% (9%, 33%) for the entire
group and 8% (1%, 23%) for patients after AlloSCT. At a me-
dian follow-up after 15.9 months (range, 3.5-36.5) after
AutoSCT for the entire group, 1-yr progression-free survival
was 77% (60%, 87%) and 1-yr overall survival was 87% (72%,
95%). For the 28 survivors after AlloSCT, median follow-up is
11.8 months (range, 0.2-33.6), 1-yr PFS is 87% (66%, 96%) and
1-yr OS is 95% (72%, 99%).
Conclusion: Busulfan based tandem AutoSCT followed by
RIC AlloSCT appears safe and effective in patients with high-
risk lymphoma. Prospective trials comparing such a strategy
to either AutoSCT or RIC AlloSCT alone in speciﬁc lymphoma
subtypes are warranted.
